# US 2017/0281795 A1 · Nucleic acid-polypeptide compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281795 A1
- Document ID: US20170281795A1
- Status: Published application
- Kind: A1
- Application number: 15/476,849
- Filed: 2017-03-31
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Avidity Biosciences, Inc.
- Applicants: Avidity Biosciences LLC
- Inventors: Andrew John GEALL; Venkata Ramana DOPPALAPUDI; David Sai-Ho CHU; Michael Caramian COCHRAN; Rachel Elizabeth JOHNS; Palani BALU; Rob BURKE; Beatrice Diana DARIMONT
- Web page: https://patentgrep.com/patent/US20170281795A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/30: from tumour cells
- C07K 16/3061: {Blood cells}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/332: Abasic residue
- C12N 2310/3513: Protein; Peptide
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

## Claims

### Claim 1

A molecule of Formula (I):
A-X-B-Y-C Formula I
wherein,
A is an antibody or its binding fragments thereof;
B is a polynucleotide;
C is a polymer;
X is a bond or first non-polymeric linker; and
Y is a bond or second linker;
wherein the polynucleotide comprises at least one 2′ modified nucleotide, at least one modified internucleotide linkage, or at least one inverted abasic moiety; and
wherein A and C are not attached to B at the same terminus.

### Claim 2 (depends on 1)

The molecule of claim 1, wherein the at least one 2′ modified nucleotide comprises 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl, 2′-deoxy, T-deoxy-2′-fluoro, 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), T-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or 2′-O-N-methylacetamido (2′-O-NMA) modified nucleotide.

### Claim 3 (depends on 1)

The molecule of claim 1, wherein the at least one 2′ modified nucleotide comprises locked nucleic acid (LNA) or ethylene nucleic acid (ENA).

### Claim 4 (depends on 1)

The molecule of claim 1, wherein the at least one modified internucleotide linkage comprises a phosphorothioate linkage or a phosphorodithioate linkage.

### Claim 5 (depends on 1)

The molecule of claim 1, wherein the at least one inverted abasic moiety is at at least one terminus.

### Claim 6 (depends on 1)

The molecule of claim 1, wherein the polynucleotide comprises a single strand.

### Claim 7 (depends on 1)

The molecule of claim 1, wherein the polynucleotide comprises a first polynucleotide and a second polynucleotide hybridized to the first polynucleotide to form a double-stranded polynucleic acid molecule.

### Claim 8 (depends on 7)

The molecule of claim 7, wherein the second polynucleotide comprises at least one modification.

### Claim 9 (depends on 7)

The molecule of claim 7, wherein the first polynucleotide and the second polynucleotide are RNA molecules.

### Claim 10 (depends on 7)

The molecule of claim 7, wherein the first polynucleotide comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NOs: 16-75, 452-1955, 1956-1962, 1967-2002, 2013-2032, 2082-2109, or 2117.

### Claim 11 (depends on 7)

The molecule of claim 7, wherein the second polynucleotide comprises a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NOs: 16-75, 452-1955, 1956-1962, 1967-2002, 2013-2032, 2082-2109, or 2117.

### Claim 12 (depends on 1)

The molecule of claim 1, wherein X and Y are independently a bond.

### Claim 13 (depends on 1)

The molecule of claim 1, wherein X and Y are independently a C1-C6 alkyl group.

### Claim 14 (depends on 1)

The molecule of claim 1, wherein X is a homobifuctional linker or a heterobifunctional linker, optionally conjugated to a C1-C6 alkyl group.

### Claim 15 (depends on 1)

The molecule of claim 1, wherein Y is a homobifuctional linker or a heterobifunctional linker.

### Claim 16 (depends on 1)

The molecule of claim 1, wherein the antibody or binding fragment thereof comprises a humanized antibody or binding fragment thereof, chimeric antibody or binding fragment thereof, monoclonal antibody or binding fragment thereof, monovalent Fab′, divalent Fab2, single-chain variable fragment (scFv), diabody, minibody, nanobody, single-domain antibody (sdAb), or camelid antibody or binding fragment thereof.

### Claim 17 (depends on 1)

The molecule of claim 1, wherein C is polyethylene glycol.

### Claim 18 (depends on 17)

The molecule of claim 17, wherein C has a molecular weight of about 1000 Da, 2000 Da, or 5000 Da.

### Claim 19 (depends on 1)

The molecule of claim 1, wherein A-X is conjugated to the 5′ end of B and Y-C is conjugated to the 3′ end of B, or Y-C is conjugated to the 5′ end of B and A-X is conjugated to the 3′ end of B.

### Claim 20 (depends on 1)

The molecule of claim 1, further comprising D, wherein D is an endosomolytic moiety.
